Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. - Wikidata - awgldk - TriplyDB

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

http://www.wikidata.org/entity/Q40263864

about

IL-6 polymorphisms: a useful genetic tool for inflammation research?Interleukin-6: an emerging regulator of pathological pain Clinical outcome measures in juvenile idiopathic arthritis Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials Treatment of juvenile idiopathic arthritis: a revolution in care What does an adult rheumatologist need to know about juvenile idiopathic arthritis?Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?Advances in the genetically complex autoinflammatory diseases IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis Juvenile Idiopathic Arthritis: Diagnosis and Treatment Adult-onset Still's disease: current challenges and future prospects Biomarkers in systemic juvenile idiopathic arthritis: a comparison with biomarkers in cryopyrin-associated periodic syndromes Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.Juvenile Idiopathic Arthritis in the Era of International Cooperation.IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia Intravenous laser blood irradiation increases efficacy of etanercept in selected subtypes of juvenile idiopathic arthritis: an innovative clinical research approach.Life-threatening complications of adult-onset Still's disease.Macrophage Activation Syndrome.Juvenile Idiopathic Arthritis 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening a Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review.What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?Managing cytokine release syndrome associated with novel T cell-engaging therapies.Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart.Treatment of adult-onset Still's disease: a review IL-6 in inflammation, immunity, and disease Toxicity management for patients receiving novel T-cell engaging therapies.Tocilizumab-Induced Acute Liver Injury in Adult Onset Still's Disease Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts.The biologic basis of clinical heterogeneity in juvenile idiopathic arthritis Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.Indications for IVIG in rheumatic diseases The development and assessment of biological treatments for children.IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases.Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.Active immunization with Tocilizumab mimotopes induces specific immune responses.Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.The varying faces of IL-6: From cardiac protection to cardiac failure.

P2860

Q24288994-809D0877-15EA-4C86-81FF-45B346D08A4F Q26748646-4EBE6D20-9FC1-428F-95C4-4220C1A5C06B Q26752701-E45D4C82-9B6A-407C-819D-3333382F814C Q26775512-D5A8E21E-E9C6-4B8D-B8F5-B6EECA556D2A Q26849497-C7200CA1-FF2C-4452-A0F1-F9D118FC40ED Q26995394-139BF22C-8CEC-4405-9CF0-BE0C6CB4C341 Q27002805-FD38F12A-010E-4866-A9BE-B6A306E22720 Q27025795-3A3E987C-276A-4A63-9716-FDC3CC4CFB49 Q28078134-AC650133-EBE0-4FB1-AD44-1EBE76B47D8B Q28079246-DB68BD98-B6F8-4BF5-8A11-5E84369262A9 Q28079446-A34901E5-EDCD-472B-81B6-360E4A5FEF15 Q28647737-B2ABC8C9-1382-4590-8F3B-69F8AC9B71FE Q30235357-1B341AF6-22A2-44FE-9A52-7AA63AA4AA0C Q30235998-82A37770-09E9-4BA2-BB60-4FF0FD1D5DCD Q30439206-DB9025FF-865F-4D1A-AFEF-9A6AC2459B3E Q31130038-1DE63F4A-21C1-4683-BE16-B696078E427E Q33412732-280AA32A-4B4E-4F6D-97A9-83C395FA1788 Q33426151-053BB911-0BF8-4BD4-81E8-B6AF4B602F5E Q33572045-E57F0246-ABB9-4E54-A9F0-DC4D43DA5B3C Q33613293-3C7D163C-F7ED-4747-917A-1CDABD09782D Q33677011-F10653E7-35D5-4127-A3C6-CC68C7E8EFD0 Q33765738-B7AC5C2E-CAD8-4213-8F0E-19AD3D1A0F58 Q33993517-722791DC-FAEE-40A3-BFF0-14D88062D884 Q34042413-E08A9FC1-01E4-4622-8A5C-7C940CA6D413 Q34043097-DEFCF101-0612-4CFF-A8DA-31410F33E726 Q34248105-C7CC3E6F-42C4-4DE4-BEC9-40220404F5A5 Q34343346-5AEF4439-8C59-43B5-8DFE-AAFF73AB4BFC Q34399037-7CD2B904-537C-413A-B8F4-9EE23DBCBB90 Q34434750-2C902096-1C55-4396-BEDD-745A216E1570 Q34530301-4528FC63-184C-43A3-A76E-B43CD5127324 Q34803472-49F6C679-08A4-438D-A9B7-75ACB10D56F6 Q35041117-E81CE4A1-200B-42BC-BF21-D213D35F6804 Q35084293-CB9C8EDE-470F-4ADA-B9FA-FD613561E958 Q35102141-4D6CE552-B079-4796-8E3E-91CF1F8F3EDD Q35135936-FEF2C1EE-8CD4-4237-9D6C-F138F944A34F Q35291353-41CD1BD0-6CFD-4E57-B4C7-EA18F33BE2B8 Q35605487-1A9CDADB-530D-48E8-A211-444240B381EE Q35649177-8197C83C-FBE6-42F9-BC3F-679EF849F7DA Q36183846-5A9DADC1-249B-4DE0-97F6-12CA4A3CE5C6 Q36368339-207DC927-0709-4BDD-BCED-62476209F30F

P2860

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

http://www.wikidata.org/entity/Q40263864

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

@en

type

label

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

@en

prefLabel

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

@en

P1433

Q40263864-61E28F5F-E49F-49A3-92E9-FB6AEF325A5E

P1476

Q40263864-B42B690A-C76D-4937-9472-006F9F0435AC

P2093

Q40263864-03F5398F-C5D0-4E19-84FE-F4901C5FC9B4

Q40263864-0F8CD1A4-2BBD-477F-B9CD-39F5A81789C1

Q40263864-130BD690-673B-4E16-A97C-CAF432301AD5

Q40263864-19037726-9981-47AB-BA29-E5BA53564E93

Q40263864-259F4206-14BD-4327-94CE-EC7799831716

Q40263864-338E69BF-20A1-4255-A66B-F2EE8267FBB2

Q40263864-38509CF7-74F3-4001-A4B9-5B7E6E7FF277

Q40263864-54BAE423-7039-42B4-8755-797947979786

Q40263864-6FF9C01E-5D25-4B74-9C54-E13A1520DC95

Q40263864-7A4DE343-BC09-4A47-A661-BBCCE09D0E98

P304

Q40263864-E56E5F2A-4338-4869-8BCE-89172AA21FF4

P31

Q40263864-067B05AF-65AF-4F33-8DE2-8DBD97E3B0B2

P356

Q40263864-5D432262-EC7B-4769-90CB-4D1576048BF5

P407

Q40263864-735B2A76-0530-45B9-BC82-15A24CFE32D7

P433

Q40263864-B504DC0E-7FAF-4E47-B4CA-E08A53E6082A

P478

Q40263864-E328CB09-FFAB-4931-9523-E63F7D06B819

P50

Q40263864-8C8D3075-5556-4FC4-97B7-5F693CB06CC8

Q40263864-954D3A39-A67D-4573-933A-705CE050617B

P577

Q40263864-E86E13F4-F451-4D49-8850-EE2FB82D8E3B

P698

Q40263864-D98389DB-4BEA-4F4F-85FB-2826AC7C2FAC

P921

Q40263864-04EA0199-C452-489E-9C66-8DE524079A93

P356

P1433

The New England Journal of Medicine

P1476

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

@en

P2093

Alberto Martini

http://www.w3.org/2001/XMLSchema#string

Alexei Grom

http://www.w3.org/2001/XMLSchema#string

Andrew Kenwright

http://www.w3.org/2001/XMLSchema#string

Angelo Ravelli

http://www.w3.org/2001/XMLSchema#string

Carine Wouters

http://www.w3.org/2001/XMLSchema#string

Daniel Lovell

http://www.w3.org/2001/XMLSchema#string

Eileen Baildam

http://www.w3.org/2001/XMLSchema#string

Fabrizio De Benedetti

http://www.w3.org/2001/XMLSchema#string

Francesco Zulian

http://www.w3.org/2001/XMLSchema#string

Hermine I Brunner

http://www.w3.org/2001/XMLSchema#string

P304

2385-2395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1112802

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P50

Rubén Burgos-Vargas

Nicolino Ruperto

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23252525

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis